Foley Hoag Represents Rinovum Women's Health in Series C Financing
December 30, 2014
Foley Hoag LLP recently represented Rinovum Women’s Health, a privately-held, U.S.-based women’s health company, in its Series C funding from an existing investor base. The company plans to use the financing to drive sales and marketing efforts, expand its products into international markets and foster innovation.
Rinovum’s mission is to bring products into the market that will enhance women's lives and empower them to take charge of their health. In July 2014, the company received FDA clearance for over-the-counter sales of its flagship product, The Stork® OTC, a conception aid for reproductive health to assist in natural conception in the privacy of the patient’s home.
The round was led by a private, Pennsylvania-based investment fund. The Pittsburgh Life Sciences Greenhouse Accelerator Fund and BlueTree Allied Angels also participated.
Foley Hoag attorneys Jeffrey Quillen and Michael Nelson represented Rinovum in the transaction.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.